For richer charts and full features, open SpikePanel on desktop.
Graded daily on value B, growth D-, profitability A-, momentum C+, revisions D-. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $JAZZ are available with SpikePanel Pro.
Key events, in time order
To present Phase 3 ACTION trial progress and novel rare brain cancer therapies
Q3 revenue +10% YoY, Xywav adds 425 net patients, Ziihera launched, FY guidance raised
Ziihera plus chemo shows significant OS benefit, strengthening its first-line position
Offering upsized from prior $1B, with concurrent share repurchases priced
Deal includes $820M upfront, adds clinical-stage precision therapy ABS-1230 for KCNT1+ epilepsy
Q2 revenue of $1.21B beat expectations, raised guidance, Amundi and BofA increased stakes confirming institutional confidence
Q2 revenue of $1.21B beat estimates; FY26 sales guidance raised above consensus; analysts lift forecasts.
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice